DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?
- PMID: 26851184
- DOI: 10.1158/2159-8290.CD-15-1321
DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?
Abstract
Precision treatment with targeted cancer drugs requires the selection of patients who are most likely to benefit from a given therapy. We argue here that the use of a combination of both DNA and transcriptome analyses will significantly improve drug response prediction.
©2016 American Association for Cancer Research.
Similar articles
-
Challenges ahead for companion diagnostics.J Natl Cancer Inst. 2012 Jan 4;104(1):14-5. doi: 10.1093/jnci/djr535. Epub 2011 Dec 14. J Natl Cancer Inst. 2012. PMID: 22173588 No abstract available.
-
Transcriptome modeling and phenotypic assays for cancer precision medicine.Arch Pharm Res. 2017 Aug;40(8):906-914. doi: 10.1007/s12272-017-0940-z. Epub 2017 Aug 1. Arch Pharm Res. 2017. PMID: 28766239 Review.
-
Personalized-medicine trials on the rise.J Natl Cancer Inst. 2012 Oct 3;104(19):1425-6. doi: 10.1093/jnci/djs432. Epub 2012 Sep 24. J Natl Cancer Inst. 2012. PMID: 23008496 No abstract available.
-
NCI-MATCH launch highlights new trial design in precision-medicine era.J Natl Cancer Inst. 2015 Jul 3;107(7):djv193. doi: 10.1093/jnci/djv193. Print 2015 Jul. J Natl Cancer Inst. 2015. PMID: 26142446 No abstract available.
-
Personalized Medicine: Genomics Trials in Oncology.Trans Am Clin Climatol Assoc. 2015;126:133-43. Trans Am Clin Climatol Assoc. 2015. PMID: 26330667 Free PMC article. Review.
Cited by
-
Molecular Biomarker of Drug Resistance Developed From Patient-Derived Organoids Predicts Survival of Colorectal Cancer Patients.Front Oncol. 2022 Mar 29;12:855674. doi: 10.3389/fonc.2022.855674. eCollection 2022. Front Oncol. 2022. PMID: 35425715 Free PMC article.
-
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.Science. 2018 Feb 23;359(6378):920-926. doi: 10.1126/science.aao2774. Science. 2018. PMID: 29472484 Free PMC article.
-
Precision medicine review: rare driver mutations and their biophysical classification.Biophys Rev. 2019 Feb;11(1):5-19. doi: 10.1007/s12551-018-0496-2. Epub 2019 Jan 4. Biophys Rev. 2019. PMID: 30610579 Free PMC article. Review.
-
Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis.BMC Med. 2022 Jul 8;20(1):219. doi: 10.1186/s12916-022-02420-2. BMC Med. 2022. PMID: 35799149 Free PMC article.
-
Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome.Cancers (Basel). 2020 Feb 1;12(2):330. doi: 10.3390/cancers12020330. Cancers (Basel). 2020. PMID: 32024067 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources